恶性与交界性卵巢肿瘤患者的生育力保存:法国ESGO认证中心经验
该连续队列研究纳入2013年2月至2019年7月在法国ESGO认证卵巢癌中心接受生育力保存的43例恶性或交界性卵巢肿瘤女性,描述多学科委员会推荐的生育力保存技术、实际使用技术、术后时间、片段数、组织学及卵泡密度或卵母细胞数量。结果显示多数为单侧(79.1%)和I期(76.7%),24例刺激取卵者平均获成熟卵12.4±12.8枚,52.6%女性冻存至少10枚成熟卵;作者建议应向此类患者提供卵母细胞和卵巢组织冻存,但需更多数据确认刺激和移植安全性。
要点
- 恶性与交界性卵巢肿瘤患者应被告知可考虑卵母细胞和卵巢组织冻存。
- 24例刺激取卵者平均获成熟卵12.4±12.8枚,52.6%冻存至少10枚。
- 卵巢组织冻存仅实施6例(提供13例),刺激取卵实施24例(提供28例)。
核心结论
- 应向恶性与交界性卵巢肿瘤患者提供卵母细胞和卵巢组织冻存。
- 卵巢刺激和卵巢组织移植的安全性仍需更多数据确认。
研究设计与样本
- 法国Tenon大学医院ESGO认证卵巢癌中心与CALG网络的连续队列研究。
- 纳入2013年2月至2019年7月接受生育力保存的43例恶性或交界性卵巢肿瘤女性。
- 主要结局为多学科委员会推荐的生育力保存技术、实际使用技术、术后时间、片段数、组织学及卵泡密度或卵母细胞数量。
主要发现
- 病理诊断:恶性上皮性卵巢肿瘤5例(11.6%),罕见恶性卵巢肿瘤14例(32.6%),交界性24例(55.8%)。
- 肿瘤多为单侧(79.1%)和I期(76.7%);诊断时平均年龄26.8±6.9岁,平均肿瘤大小109.7±61 mm。
- 生育力保存前平均AFC为11.0±6.1,AMH水平为2.7±4.6 ng/mL。
- 卵巢组织冻存实施6例(提供13例);卵巢刺激取卵冻存实施24例(提供28例),术后中位间隔188天。
- 每次刺激平均获成熟卵12.4±12.8枚;52.6%的女性冻存至少10枚成熟卵;5例女性未获生育力保存提议。
临床怎么用
- 对恶性与交界性卵巢肿瘤患者,应个体化提供卵母细胞和卵巢组织冻存咨询。
- 多学科委员会可评估并推荐生育力保存技术,实际实施需结合患者情况。
局限性
- 样本量较小(43例),部分技术实施例数少(卵巢组织冻存仅6例)。
- 卵巢刺激和卵巢组织移植的安全性需更多数据确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe strategy and results of fertility preservation (FP) in patients with malignant and borderline ovarian tumors. METHODS: Consecutive cohort study of 43 women with malignant or borderline ovarian tumors who underwent FP between February 2013 and July 2019. The study was conducted in national expert center in Tenon University Hospital, Sorbonne University: French ESGO-certified ovarian cancer center and pregnancy-associated cancer network (CALG). Main outcome measure was FP technique proposed by multidisciplinary committee, FP technique used, time after surgery, number of fragments, histology and follicle density (if ovarian tissue freezing), number of expected, retrieved and frozen oocytes (if ovarian stimulation). RESULTS: Pathological diagnosis was malignant epithelial ovarian tumor in five women (11.6%), rare malignant ovarian tumor in 14 (32.6%), borderline in 24 (55.8%), and mostly unilateral (79.1%) and stage I (76.7%). Mean age at diagnosis was 26.8 ± 6.9 years and mean tumor size 109.7 ± 61 mm. Before FP, mean AFC was 11.0 ± 6.1 and AMH levels were 2.7 ± 4.6 ng/mL. Six ovarian tissue-freezing procedures were performed (offered to 13). Twenty-four procedures of ovarian stimulation and oocyte freezing were performed after surgical treatment for 19 women (offered to 28) with a median interval of 188 days. The mean number of mature oocytes retrieved per stimulation was 12.4 ± 12.8. At least 10 mature oocytes were frozen for 52.6% of the women. No FP was offered to five women. CONCLUSION: Oocyte and ovarian tissue cryopreservation should be offered to patients with malignant and borderline ovarian tumors. More data are needed to confirm ovarian stimulation and ovarian tissue grafting safety.
引用
- Geoffron S, Lier A, de Kermadec E, et al. Fertility preservation in women with malignant and borderline ovarian tumors: Experience of the French ESGO-certified center and pregnancy-associated cancer network (CALG). Gynecol Oncol. 2021. PMID: 33812696. doi:10.1016/j.ygyno.2021.03.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。